4//SEC Filing
Jones Aranthan II 4
Accession 0001209191-21-014873
CIK 0001347178other
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 5:17 PM ET
Size
14.1 KB
Accession
0001209191-21-014873
Insider Transaction Report
Form 4
Jones Aranthan II
Chief Corp. Affairs Officer
Transactions
- Award
Common Stock
2021-02-24+25,800→ 101,287 total - Exercise/Conversion
Common Stock
2021-02-24$12.27/sh+22,499$276,063→ 123,786 total - Sale
Common Stock
2021-02-24$20.01/sh−22,986$460,033→ 100,800 total - Award
Employee Stock Option (Right to Buy)
2021-02-24+61,200→ 61,200 totalExercise: $20.28Exp: 2031-02-23→ Common Stock (61,200 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-02-24−22,499→ 37,501 totalExercise: $12.27Exp: 2029-07-24→ Common Stock (22,499 underlying)
Footnotes (5)
- [F1]Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- [F2]A portion of the shares were sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F4]The option vests with respect to 25% of the underlying shares on February 24, 2022, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.
- [F5]The option vested and became exercisable with respect to 25% of the shares subject to the option on July 25, 2020, and the remaining 75% of the shares vests in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the issuer through each monthly vesting date.
Documents
Issuer
Vanda Pharmaceuticals Inc.
CIK 0001347178
Entity typeother
Related Parties
1- filerCIK 0001785894
Filing Metadata
- Form type
- 4
- Filed
- Feb 25, 7:00 PM ET
- Accepted
- Feb 26, 5:17 PM ET
- Size
- 14.1 KB